Progressive Clinical Research

The oral Janus kinase/spleen tyrosine kinase inhibitor<scp>ASN</scp>002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study

Robert Bissonnette, Catherine Maari, Seth Forman et al. · British Journal of Dermatology · 2019 · 129 citations · Full text

Medicine, Dermatology, Pharmacology +17

Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study

Howard Sofen, Robert Bissonnette, Gil Yosipovitch et al. · EClinicalMedicine · 2023 · 99 citations · Full text

Life Sciences, Immunology, Pharmacology +9

A calcipotriene/betamethasone dipropionate two‐compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8‐week, double‐blind phase of a clinical trial

Stephen K. Tyring, Natalia Mendoza, Melanie Appell et al. · International Journal of Dermatology · 2010 · 45 citations

Pharmacy, Dermatology, Pharmacotherapy +8

A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis

Robert Bissonnette, Robert S. Call, Tooraj Joseph Raoof et al. · American Journal of Clinical Dermatology · 2022 · 41 citations · Full text

Medicine, Dermatology, Pharmacology +16

Oral spleen tyrosine kinase/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: Results of a randomized phase 2 study

Pablo A. Jimenez, Howard Sofen, Robert Bissonnette et al. · Journal of the American Academy of Dermatology · 2023 · 41 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13